Global Antibody Partnering Terms and Agreements Directory 2014-2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 17, 2019--
The “Global Antibody Partnering Terms and Agreements 2014-2019: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering.
The Global Antibody Partnering Terms and Agreements 2014 to 2019 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
This report contains over 1,100 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of Antibody dealmaking and business activities.
Key Topics Covered:
2. Trends in antibody dealmaking
2.2. Antibody partnering over the years
2.3. Most active antibody dealmakers
2.4. Antibody partnering by deal type
2.5. Antibody partnering by therapy area
2.6. Deal terms for antibody partnering
2.6.1 Antibody partnering headline values
2.6.2 Antibody deal upfront payments
2.6.3 Antibody deal milestone payments
2.6.4 Antibody royalty rates
3. Leading antibody deals
3.2. Top antibody deals by value
4. Most active antibody dealmakers
4.2. Most active antibody dealmakers
4.3. Most active antibody partnering company profiles
5. Antibody contracts dealmaking directory
5.2. Antibody contracts dealmaking directory
6. Antibody dealmaking by technology type
7. Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendix 1 - Antibody deals by company A-Z
Appendix 2 - Antibody deals by stage of development
Appendix 3 - Antibody deals by deal type
Appendix 4 - Antibody deals by therapy area
Appendix 5 - Deal type definitions
For more information about this report visit https://www.researchandmarkets.com/r/542k61
View source version on businesswire.com:https://www.businesswire.com/news/home/20190517005383/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/17/2019 11:29 AM/DISC: 05/17/2019 11:29 AM